KR20100125618A - A method for preparation of fermented red ginseng drink mixed with medical plants extracts and a drink composition comprising the same - Google Patents
A method for preparation of fermented red ginseng drink mixed with medical plants extracts and a drink composition comprising the same Download PDFInfo
- Publication number
- KR20100125618A KR20100125618A KR1020090044419A KR20090044419A KR20100125618A KR 20100125618 A KR20100125618 A KR 20100125618A KR 1020090044419 A KR1020090044419 A KR 1020090044419A KR 20090044419 A KR20090044419 A KR 20090044419A KR 20100125618 A KR20100125618 A KR 20100125618A
- Authority
- KR
- South Korea
- Prior art keywords
- red ginseng
- extract
- fermented
- fermented red
- concentrate
- Prior art date
Links
- 235000002789 Panax ginseng Nutrition 0.000 title claims abstract description 92
- 239000000284 extract Substances 0.000 title claims abstract description 69
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 238000000034 method Methods 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 title description 7
- 241000196324 Embryophyta Species 0.000 title description 3
- 235000013361 beverage Nutrition 0.000 claims abstract description 27
- 230000000291 postprandial effect Effects 0.000 claims abstract description 8
- -1 raliae Species 0.000 claims abstract description 8
- 241000282461 Canis lupus Species 0.000 claims abstract description 6
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 6
- 244000197580 Poria cocos Species 0.000 claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 241000186840 Lactobacillus fermentum Species 0.000 claims abstract description 5
- 229940012969 lactobacillus fermentum Drugs 0.000 claims abstract description 5
- 239000012141 concentrate Substances 0.000 claims description 30
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 24
- 239000008280 blood Substances 0.000 claims description 19
- 210000004369 blood Anatomy 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 206010012601 diabetes mellitus Diseases 0.000 claims description 16
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- 239000008213 purified water Substances 0.000 claims description 13
- 241000894006 Bacteria Species 0.000 claims description 12
- 238000000855 fermentation Methods 0.000 claims description 12
- 230000004151 fermentation Effects 0.000 claims description 12
- 239000004310 lactic acid Substances 0.000 claims description 12
- 235000014655 lactic acid Nutrition 0.000 claims description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- 240000008397 Ganoderma lucidum Species 0.000 claims description 10
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 10
- 235000000346 sugar Nutrition 0.000 claims description 10
- 235000008708 Morus alba Nutrition 0.000 claims description 9
- 240000000249 Morus alba Species 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 7
- 241001248610 Ophiocordyceps sinensis Species 0.000 claims description 6
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 5
- 229930003268 Vitamin C Natural products 0.000 claims description 5
- 229940107702 grapefruit seed extract Drugs 0.000 claims description 5
- 229940069445 licorice extract Drugs 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- 235000019154 vitamin C Nutrition 0.000 claims description 5
- 239000011718 vitamin C Substances 0.000 claims description 5
- 235000008216 herbs Nutrition 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 229920001100 Polydextrose Polymers 0.000 claims description 3
- 239000001259 polydextrose Substances 0.000 claims description 3
- 235000013856 polydextrose Nutrition 0.000 claims description 3
- 229940035035 polydextrose Drugs 0.000 claims description 3
- 235000013399 edible fruits Nutrition 0.000 claims description 2
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 2
- 240000005979 Hordeum vulgare Species 0.000 claims 1
- 235000007340 Hordeum vulgare Nutrition 0.000 claims 1
- 239000007788 liquid Substances 0.000 abstract description 9
- 230000003178 anti-diabetic effect Effects 0.000 abstract description 6
- 230000002218 hypoglycaemic effect Effects 0.000 abstract description 5
- 239000003472 antidiabetic agent Substances 0.000 abstract description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 15
- 239000008103 glucose Substances 0.000 description 15
- 108010028144 alpha-Glucosidases Proteins 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 12
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 11
- 241000411851 herbal medicine Species 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- 241000125175 Angelica Species 0.000 description 7
- 235000001287 Guettarda speciosa Nutrition 0.000 description 7
- 102000004139 alpha-Amylases Human genes 0.000 description 7
- 108090000637 alpha-Amylases Proteins 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 229940024171 alpha-amylase Drugs 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 229930182490 saponin Natural products 0.000 description 6
- 235000017709 saponins Nutrition 0.000 description 6
- 230000001953 sensory effect Effects 0.000 description 6
- 240000008415 Lactuca sativa Species 0.000 description 5
- 235000003228 Lactuca sativa Nutrition 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 239000004382 Amylase Substances 0.000 description 4
- 108010065511 Amylases Proteins 0.000 description 4
- 102000013142 Amylases Human genes 0.000 description 4
- 241000208340 Araliaceae Species 0.000 description 4
- 108010059892 Cellulase Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 description 4
- 235000019418 amylase Nutrition 0.000 description 4
- 229940106157 cellulase Drugs 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 235000008434 ginseng Nutrition 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000002075 main ingredient Substances 0.000 description 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 4
- 150000007949 saponins Chemical class 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 3
- 241000190633 Cordyceps Species 0.000 description 3
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 3
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 3
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229960002632 acarbose Drugs 0.000 description 3
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229940010454 licorice Drugs 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 238000010025 steaming Methods 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- LWFUFLREGJMOIZ-UHFFFAOYSA-N 3,5-dinitrosalicylic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1O LWFUFLREGJMOIZ-UHFFFAOYSA-N 0.000 description 2
- HDHRTQZSBFUBMJ-UHFFFAOYSA-N Artonin E Natural products O1C2=C3C=CC(C)(C)OC3=CC(O)=C2C(=O)C(CC=C(C)C)=C1C1=CC(O)=C(O)C=C1O HDHRTQZSBFUBMJ-UHFFFAOYSA-N 0.000 description 2
- 241000202807 Glycyrrhiza Species 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- GDQXJMLXEYSICD-UHFFFAOYSA-N cyclomorusin A Chemical compound C1=CC(C)(C)OC2=CC(O)=C(C(=O)C=3C(C=C(C)C)OC=4C(=CC=C(O)C=4)C=3O3)C3=C21 GDQXJMLXEYSICD-UHFFFAOYSA-N 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- FVIZARNDLVOMSU-UHFFFAOYSA-N ginsenoside K Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O FVIZARNDLVOMSU-UHFFFAOYSA-N 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- WUBUWBUVAKMGCO-UHFFFAOYSA-N morusin Natural products CC(=CCC1=C(Cc2c3C=CC(C)(C)Oc3cc(O)c2C1=O)c4ccc(O)cc4O)C WUBUWBUVAKMGCO-UHFFFAOYSA-N 0.000 description 2
- XFFOMNJIDRDDLQ-UHFFFAOYSA-N morusin Chemical compound O1C2=C3C=CC(C)(C)OC3=CC(O)=C2C(=O)C(CC=C(C)C)=C1C1=CC=C(O)C=C1O XFFOMNJIDRDDLQ-UHFFFAOYSA-N 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000018791 negative regulation of catalytic activity Effects 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 229940095679 poly-dex Drugs 0.000 description 2
- 239000008057 potassium phosphate buffer Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 description 1
- IFBHRQDFSNCLOZ-ZIQFBCGOSA-N 4-nitrophenyl alpha-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C([N+]([O-])=O)C=C1 IFBHRQDFSNCLOZ-ZIQFBCGOSA-N 0.000 description 1
- HOMSOWZTBJWNHP-UHFFFAOYSA-N 5-chlorothiadiazole Chemical compound ClC1=CN=NS1 HOMSOWZTBJWNHP-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 101100004286 Caenorhabditis elegans best-5 gene Proteins 0.000 description 1
- DAYVKEVMSODOPS-UHFFFAOYSA-N Cyclomorusin Natural products CC(=CC1Oc2ccccc2C3=C1C(=O)c4c(O)cc5OC(C)(C)C=Cc5c4O3)C DAYVKEVMSODOPS-UHFFFAOYSA-N 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 229930182734 Sanggenon Natural products 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 239000003392 amylase inhibitor Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000020650 eye health related herbal supplements Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 229940029988 ginseng preparation Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229930190765 kuwanone Natural products 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- VDYCLYGKCGVBHN-UHFFFAOYSA-N pachymaic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC(=C)C(C)C)C(O)=O)C(O)CC21C VDYCLYGKCGVBHN-UHFFFAOYSA-N 0.000 description 1
- SRDNLMOBFKJOSD-UHFFFAOYSA-N pachymic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C(O)=O)C(O)CC21C SRDNLMOBFKJOSD-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- LJCNRYVRMXRIQR-UHFFFAOYSA-L potassium sodium tartrate Chemical compound [Na+].[K+].[O-]C(=O)C(O)C(O)C([O-])=O LJCNRYVRMXRIQR-UHFFFAOYSA-L 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/70—Clarifying or fining of non-alcoholic beverages; Removing unwanted matter
- A23L2/72—Clarifying or fining of non-alcoholic beverages; Removing unwanted matter by filtration
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/032—Citric acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/208—Fungi extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/708—Vitamin C
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/24—Heat, thermal treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Non-Alcoholic Beverages (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 홍삼액을 유산균으로 발효시킨 발효홍삼액과, 홍삼, 상엽, 상백피, 당귀, 백복령, 총목피 각각의 추출액에 유산균을 첨가, 발효시킨 한약재 혼합 발효 홍삼 농축액을 포함하는 것을 특징으로 하는 항당뇨 효능이 있는 발효 홍삼 음료 조성물 및 이의 제조방법에 관한 것이다.Anti-diabetic effect of the present invention comprises fermented red ginseng liquid fermented red ginseng liquid and lactic acid bacteria, fermented red ginseng extract to each of the extracts of red ginseng, upper leaf, Sangbaekpi, Angelica, Baekbokryeong, and Bark bark It relates to a fermented red ginseng beverage composition and a method for producing the same.
만성퇴행성질병 가운데 당뇨는 아직까지 완전한 치료가 어려운 대사성 질환으로, 세계적으로 상당히 높은 발병률을 보이고 있고, 우리나라 또한 식생활 및 생활습관의 서구화와 관련하여 그 유병률이 급증하고 있다. Among chronic degenerative diseases, diabetes is a metabolic disease that is not yet completely curable, and has a very high incidence rate in the world, and the prevalence rate of Korea is also rapidly increasing in relation to westernization of diet and lifestyle.
당뇨병은 췌장에서 인슐린을 충분히 분비하지 못하여 발생하는 인슐린 의존형 당뇨병과 신체 내의 세포가 인슐린에 대한 저항성을 나타낼 때 발병하는 인슐린 비의존형 당뇨(2형 당뇨)가 있으며, 대다수의 환자들이 치료법으로 경구혈당강하제를 복용하고 있으나, 심한 유산혈증과 저혈당의 부작용을 동반하여 문제가 되고 있다. Diabetes includes insulin-dependent diabetes, which is caused by insufficient insulin from the pancreas, and insulin-independent diabetes (type 2 diabetes), which occurs when cells in the body exhibit insulin resistance, and most patients treat oral hypoglycemics as a treatment. Is taking, but has been a problem with side effects of severe lactic acidosis and hypoglycemia.
최근에는 α-글루코시다제의 기능을 억제하여 포도당의 흡수를 지연시켜 식후 고혈당과 고인슐린혈증을 개선시킬 수 있는 acarbose와 같은 α-글루코시다제 억제제가 사용되고 있다. 그러나 현재까지 당뇨병은 그 완치법이 확립되어 있지 않고 있다.Recently, α-glucosidase inhibitors such as acarbose have been used to inhibit the function of α-glucosidase to delay glucose absorption and improve postprandial hyperglycemia and hyperinsulinemia. However, until now, diabetes has not been fully cured.
최근에는 지금까지 민간요법적으로 사용되어오던 한약재나 천연물로부터 당뇨의 억제 및 개선에 효능이 있는 소재를 찾으려는 연구가 많이 진행되고 있고, 또한 이러한 항당뇨 기능성 소재들을 부작용이 없는 식품의 형태로 섭취하려는 시도도 진행되고 있다.Recently, many researches have been conducted to find ingredients that are effective in suppressing and improving diabetes from herbal medicines or natural products that have been used folk remedies until now, and also ingested these anti-diabetic functional ingredients in the form of foods without side effects. Attempts are being made.
홍삼은 인삼을 증숙하여 말리는 홍삼화 과정에서 인체에 약리작용을 하는 사포닌들이 많이 생성이 되고, 유산균 발효에 의해 사포닌배당체의 당이 분해되어 흡수되기 쉬운 형태의 사포닌으로 전환되므로 홍삼의 약리작용을 증진시켜 준다고 알려져 있다. Red ginseng produces saponins that have pharmacological effects on the human body in the process of red ginseng drying by steaming ginseng, and the sugars of saponin glycosides are converted into saponins that are easily absorbed by lactic acid bacteria and thus promoted pharmacological action of red ginseng. It is known to let you.
발효홍삼은 이러한 장내미생물의 차이로 인한 효능과 흡수율의 차이를 없애기 위해 홍삼을 미리 장내미생물로 발효시킴으로써 개인차를 극복하고 체내 흡수율을 증대시키고자 한 것이다. 발효홍삼에 많이 함유되어 있는 사포닌 성분인 진세노사이드 Rg3, Rh1, Rh2. 화합물 K등은 혈당개선 효능이 있는 것으로 보고되어 있다.Fermented red ginseng is intended to overcome individual differences and increase the body's absorption rate by fermenting red ginseng into intestinal microorganisms in advance in order to eliminate the difference in efficacy and absorption rate due to the difference in intestinal microorganisms. Ginsenosides Rg3, Rh1, Rh2, which are saponin components contained in fermented red ginseng. Compound K and the like have been reported to have an effect on improving blood sugar.
상엽은 본초강목 등의 동양의약서에 상백피와 함께 소갈증에 효과가 있음이 기록되어 있으며, 최근에는 1-데옥시노지리마이신(deoxynojirimycin)(DNJ) 및 그밖에 함유되어 있는 알칼로이드가 혈당강하 효과를 나타내는 것으로 밝혀졌다. It has been reported that the upper lobe has an effect on small thirst with baekpipi in oriental medicines such as medicinal herb, and recently, 1-deoxynojirimycin (DNJ) and other alkaloids have hypoglycemic effect. It turned out.
상백피는 뽕나무의 뿌리껍질로써 주요 생리활성성분으로는 모루신(morusin), 사이클로모루신(cyclomorusin), 상게논(sanggenon) A-E, 쿠와논(Kuwanone) A,B 및 C, 지방산등이 알려져 있고, 혈혈중으로의 포도당 유입을 차단하여 고혈당을 예방할 수 있음이 보고되었으며, 간보호 효과도 보고되어져 있다. Morusin is the root bark of mulberry tree and its main bioactive components are morusin, cyclomorusin, sanggenon AE, Kuwanone A, B and C, and fatty acids. In addition, it has been reported that the prevention of hyperglycemia can be prevented by blocking the influx of glucose into the blood, and hepatoprotective effects have been reported.
당귀는 미나리과에 속하는 다년생 초본으로 올리고당, 쿠마린 및 정유성분을 주성분으로 함유하고 있으며, 진정작용, 진통작용, 항균작용, 항산화작용, 이담작용등이 있다.Angelica is a perennial herb belonging to Apiaceae, which contains oligosaccharides, coumarins and essential oils as main ingredients, and has sedative, analgesic, antibacterial, antioxidant and edema effects.
백복령은 소나무류 뿌리주위에 기생하는 균핵으로 전통의학에서 진정, 이뇨, 강장, 혈당을 낮추는 작용 등으로 여러 처방에 빈용되고 있는 한약제로, 주요 성분은 pachymic acid로 대표되는 트리테르펜계 화합물이다.Baekbokryeong is a parasitic nucleus that is parasitic around the roots of pine trees, and is traditionally used in various medicines to reduce sedation, diuresis, tonic, and blood sugar in traditional medicine. The main ingredient is triterpene compound represented by pachymic acid.
총목피는 두릅나무 껍질을 말린 것으로 사포닌성 배당체인 아랄로시드(타랄린)이 약리작용을 나타내는 주요 성분이다. 총목피는 ‘동의보감에서 당뇨에 치료효과가 있다고 하였으며, 이뇨작용을 하여 신장기능강화에도 도움을 준다고 하였다. The bark of dried bark is a major component of pharmacological action of the saponin glycoside, Araloxide (Talolin). Chong Mokpi said, 'It is said that there is a therapeutic effect on diabetes in the sense of consent and it also helps strengthen kidney function by acting as a diuretic.
본 발명은 항당뇨 작용 및 식후 혈당강하 작용이 우수하여 당뇨 및 합병증 예방, 치료에 유용한, 한약재 혼합 발효홍삼 음료의 제조 방법 방법과 이를 포함하는 음료 조성물을 제공하는 데 목적이 있다.The present invention is excellent in antidiabetic action and postprandial hypoglycemic action, and is useful for preventing and treating diabetes and complications.
본 발명은, The present invention,
홍삼(Red Genseng)액에 유산균을 첨가하여 발효시키고 농축시켜 발효 홍삼 농축액을 수득하는 단계; Adding red lactic acid bacteria to red ginseng ( Red Genseng ) solution to ferment and concentrate to obtain fermented red ginseng concentrate;
홍삼, 상엽(Mulberry leaves, Mori folium), 상백피(Moris alba L.), 당귀(Angeliae), 백복령(Poria cocos Wolf), 총목피(Araliae Cortex)의 추출액을 유산균으로 발효시키고 농축시켜 한약재 혼합 발효 홍삼 농축액을 수득하는 단계; 및 Red ginseng, Mulberry leaves (Mori folium ), Morus alba L. , Angelica, Angelica, Poria cocos Wolf and Araliae Cortex extracts are fermented and concentrated by lactic acid bacteria Obtaining a concentrate; And
상기 발효 홍삼 농축액과 상기 한약재 혼합 발효 홍삼 농축액을 혼합하여 발효홍삼 음료를 제조하는 것을 특징으로 하는, 당뇨예방 또는 식후 혈당 개선용 발효 홍삼 음료의 제조 방법에 관한 것이다.The fermented red ginseng concentrate and fermented red ginseng concentrate by mixing the fermented red ginseng concentrate, characterized in that for producing a fermented red ginseng beverage, diabetes prevention or post-prandial blood glucose improvement method for producing a fermented red ginseng beverage.
본 발명에 따른 방법에서, 상기 유산균은 락토바실러스속이나 스트렙토코쿠스속 등의 통상적으로 공지된 유산균이 사용될 수 있으며, 바람직하게는 Lactobacillus fermentum NUC-C1 KCCM10929P이나, 이에 한정되는 것은 아니다. 상기 유산균을 첨가한 후 40 내지 42℃에서 24 내지 48시간 발효시킨다.In the method according to the present invention, the lactic acid bacteria may be commonly used lactic acid bacteria such as Lactobacillus genus or Streptococcus genus, preferably Lactobacillus fermentum NUC-C1 KCCM10929P, but is not limited thereto. After the addition of the lactic acid bacteria fermentation at 40 to 42 ℃ 24 to 48 hours.
본 발명의 한 양태에서, 상기 홍삼액은 발효홍삼 제조기 등을 사용하여 4년근 이상된 인삼을 증숙하고, 숙성시키는 방법으로 제조될 수 있다. 당해 증숙 단계는 90 내지 95℃에서 20 내지 24시간 동안 이루어지며, 당해 숙성 단계에는 48시간 내외가 소요된다. In one embodiment of the present invention, the red ginseng liquid may be prepared by steaming and ripening ginseng aged more than 4 years using fermented red ginseng making machine and the like. The steaming step is carried out at 90 to 95 ℃ for 20 to 24 hours, the aging step takes about 48 hours.
본 발명의 한 양태에서, 상기 상엽(Mulberry leaves, Mori folium), 상백 피(Moris alba L.), 당귀(Angeliae), 백복령(Poria cocos Wolf), 총목피(Araliae Cortex)는 약탕기를 이용하여 상엽, 상백피, 백복령, 당귀, 총목피 각각에 약 10배 중량부의 물을 첨가하여 약 95℃ 이상에서 1시간 내지 3시간, 바람직하게는 2시간 내지 2시간 30분 추출시킨다. In one embodiment of the present invention, the mulberry leaves (Moli folium ), Morus alba L. , Angelica (Angeliae), Baekbokyeong (Poria cocos Wolf), Araliae Cortex (Araliae Cortex) using a medicinal herb In addition, about 10 times by weight of water is added to each of baekbaekpi, baekbokyeong, Angelica, total bark and extracted for 1 hour to 3 hours, preferably 2 hours to 2 hours 30 minutes at about 95 ℃ or more.
본 발명의 한 양태에서, 상기 한약재 추출액을 혼합하여 발효 및 농축하는 단계는 발효되지 않은 홍삼액 30%, 상엽추출액 20%, 상백피추출액 20%, 당귀추출액 10%, 총목피추출액 10%, 백복령추출액 10%를 혼합하여 홍삼발효와 같은 방법으로 발효하여 농축시킨다.In one embodiment of the present invention, the step of mixing and fermenting the medicinal herb extract is not fermented red ginseng extract 30%, lettuce extract 20%, lettuce extract 20%, Angelica extract 10%, total tree extract 10%, Baekbokyeong extract 10 Mix% and ferment and concentrate in the same way as red ginseng fermentation.
본 발명의 한 양태에 따른 한약재 추출액의 발효 및 농축 단계에서, 발효되지 않은 홍삼액 대신 유산균으로 발효된 홍삼액을 사용하거나, 홍삼액 성분을 제외한 나머지 한약재들만으로 발효 및 농축시킬 수 있다.In the fermentation and concentration step of the herbal medicine extract according to an embodiment of the present invention, red ginseng liquid fermented with lactic acid bacteria instead of the non-fermented red ginseng liquid, or can be fermented and concentrated with only the other herbal ingredients except the red ginseng liquid component.
본 발명의 한 양태에서, 발효홍삼농축액 베이스와 한약재 혼합 발효홍삼농축액 베이스로 홍삼음료 조성물을 제조하며, 구체적인 예로는 발효홍삼농축액(Brix32), 한약재 혼합 홍삼농축액(Brix34), 헛개나무 추출액(Brix50), 천궁추출액(Brix50), 동충하초 추출액(Brix50), 쌍화 추출액(Brix50), 영지 추출액(Brix50), 감초 추출액(Brix50), 나한과추출물, 복합황금추출물, 구연산, 비타민 C, 자몽종자추출물, 폴리덱스트로즈(중합체 90%), 정제수 등과 혼합하여 음료 혼합물을 생성한다.In one embodiment of the present invention, the red ginseng beverage composition is prepared from the fermented red ginseng concentrate base and the herbal medicine mixed fermented red ginseng concentrate base, and specific examples are the fermented red ginseng concentrate (Brix32), the herbal medicine mixed red ginseng concentrate (Brix34), the bark tree extract (Brix50) , Cheongung Extract (Brix50), Cordyceps Sinensis Extract (Brix50), Ssanghwa Extract (Brix50), Ganoderma Lucidum Extract (Brix50), Licorice Extract (Brix50), Herb Extract, Complex Golden Extract, Citric Acid, Vitamin C, Grapefruit Seed Extract, Polydex A beverage mixture is formed by mixing with troz (90% polymer), purified water and the like.
본 발명의 한 양태에서, 배합 조성물을 여과한 후 음료 혼합물을 80 내지 120℃의 온도, 바람직하게는 98℃의 온도에서 2 내지 5분간 살균한다. 살균이 완료 되면 음료 혼합물에 복합허브향 0.2g을 첨가한다. 본 발명의 한 양태에서, 허브향이 첨가된 음료 혼합물을 용기에 충진하여 냉각한 후 캡으로 밀봉한다.In one embodiment of the invention, the blend composition is filtered and then the beverage mixture is sterilized for 2 to 5 minutes at a temperature of 80 to 120 ° C, preferably at 98 ° C. When the sterilization is complete, add 0.2 g of the mixed herb flavor to the beverage mixture. In one embodiment of the present invention, the herbal mixture to which the beverage mixture is added is cooled by filling into a container and then sealed with a cap.
본 발명은 또한 홍삼의 유산균 발효액과, 홍삼, 상엽(Mulberry leaves, Mori folium), 상백피(Moris alba L.), 당귀(Angeliae), 백복령(Poria cocos Wolf) 및 총목피(Araliae Cortex)의 추출액의 유산균 발효액을 포함하는, 당뇨예방 또는 식후 혈당 개선용 발효홍삼 음료용 조성물에 관한 것이다.The present invention also relates to the extracts of lactic acid bacteria fermentation broth of red ginseng, and extracts of red ginseng, mulberry leaves, Mori folium , Moris alba L. , Angelica, Angelica, Poria cocos Wolf and Araliae Cortex. It relates to a composition for fermented red ginseng beverage for diabetic prevention or postprandial blood sugar improvement, including a lactic acid bacteria fermentation broth.
본 발명에 따른 발효 홍삼 음료용 조성물은, 헛개나무 추출액, 천궁추출액, 동충하초 추출액, 쌍화 추출액, 영지 추출액, 감초 추출액, 나한과추출물, 복합황금추출물, 구연산, 비타민 C, 자몽종자추출물, 폴리덱스트로즈(중합체 90%) 및 정제수를 추가로 포함할 수 있다.Fermented red ginseng beverage composition according to the present invention, the bark extract, Cheongung extract, Cordyceps sinensis extract, Ssanghwa extract, Ganoderma lucidum extract, licorice extract, Namiaceae extract, complex golden extract, citric acid, vitamin C, grapefruit seed extract, polydex Rose (90% polymer) and purified water may further be included.
본 발명에 따른 항당뇨 효능이 있는 발효홍삼 농축액과 한약재 첨가 발효홍삼 농축액을 주원료로 하고 여러 가지 한방추출엑기스를 부원료로 혼합된 발효홍삼 음료조성물은 음용 시 면역증진, 원기회복의 효과를 기대할 수 있고, 또한 발효에 의해 생성된 Rg3, Rh1, Rh2, 화합물 K와 같은 홍삼의 유효 사포닌에 의해 혈당개선 및 당뇨예방의 효과를 기대할 수 있다.Fermented red ginseng concentrate with antidiabetic effect according to the present invention and fermented red ginseng concentrate added with medicinal herbs as a main ingredient and fermented red ginseng beverage composition mixed with various herbal extract extracts can be expected to increase the effects of immuno-stimulation and refreshment during drinking. In addition, the effective saponin of red ginseng such as Rg3, Rh1, Rh2, and Compound K produced by fermentation can be expected to improve blood glucose and prevent diabetes.
이하, 실시예를 통하여 본 발명을 보다 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다. Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are only for illustrating the present invention more specifically, and the scope of the present invention is not limited by these examples in accordance with the gist of the present invention.
실시예 1) 발효홍삼 농축액의 제조Example 1 Preparation of Fermented Red Ginseng Concentrate
엔유씨 발효홍삼 제조기를 사용하여 4년근 이상된 인삼을 90~95℃에서 20~24시간 증숙하고, 90~95℃에서, 48시간 내외로 숙성시켜 홍삼액을 제조한 후 유산균 Lactobacillus fermentum NUC-C1 KCCM10929P를 0.1 중량 % 첨가하여 40℃~42℃에서 24~48시간 발효한 후 Brix 32~35가 되게 농축하여 제조하였다.Using ginseng fermented red ginseng, steamed ginseng aged more than 4 years at 90-95 ℃ for 20-24 hours, aged at 90-95 ℃ for 48 hours to produce red ginseng solution, and then Lactobacillus fermentum NUC-C1 KCCM10929P 0.1 wt% was added and fermented at 40 ° C.-42 ° C. for 24 to 48 hours, followed by concentration to Brix 32 to 35.
실시예 2) 한약재 첨가 발효홍삼 농축액의 제조Example 2 Preparation of Fermented Red Ginseng Concentrate Added with Herbal Medicine
2-1 한약재 추출액 제조2-1 Herbal Medicine Extract Preparation
엔유씨 약탕기를 이용하여 상엽, 상백피, 백복령, 당귀, 총목피 각각에 10배 중량부의 물을 첨가하여 95℃ 이상에서 2시간~3시간 2회 추출하여 여과지로 여과하여 각각의 한약재 추출액을 제조하였다. Each medicinal herb extract was prepared by adding 10-fold by weight of water to each of the upper leaves, lettuce leaves, Baekbokyeong, Angelica, and total bark using NYU C. tanggi, and extracting twice at 95 ° C. for 2 hours to 3 hours.
2-2 홍삼액과 한약재 추출액의 혼합액 제조2-2 Preparation of Mixed Ginseng Extract and Red Herb Extract
상기 실시예 1의 방법으로 제조한 홍삼액(발효전) 30 중량%, 상엽추출액 20 중량%, 상백피추출액 20 중량%, 백복령추출액 10 중량%, 당귀추출액 10 중량%, 총목피추출액 10 중량%를 혼합한 한약재 혼합 홍삼액을 제조하였다30% by weight of red ginseng extract (prior to fermentation) prepared by the method of Example 1, 20% by weight of lettuce extract, 20% by weight of lettuce extract, 10% by weight of Baekbokyeong extract, 10% by weight of Angelica extract, 10% by weight of total tree extract Korean herbal medicine mixed red ginseng liquid was prepared
2-3 한약재 혼합 홍삼액의 발효·농축액 제조2-3 Fermentation and Concentration Preparation of Red Ginseng Extract
한약재가 비율별로 혼합된 홍삼액을 상기 실시예 1의 발효홍삼제조와 같은 방법으로 발효·농축(Brix32~35)하였다.The red ginseng liquid mixed with the medicinal herb ratio was fermented and concentrated in the same manner as in the fermented red ginseng preparation of Example 1 (Brix 32-35).
실시예 3) 음료조성물을 배합 및 음료제조Example 3 Formulation of Beverage Compositions and Beverage Preparation
주원료인 발효홍삼농축액(Brix32) 2~3g과 한약재 혼합 발효홍삼농축액(Brix34) 6~7g, 홍삼음료 제조용 부원료인 헛개나무 추출액(Brix50) 2~4.4g, 천궁추출액(Brix50) 2.8~4.0g, 동충하초 추출액(Brix50) 3.0~4.5g, 쌍화 추출액(Brix50) 2.7~5.0g, 영지 추출액(Brix50) 2.4~3.9g, 감초 추출액(Brix50) 3.4~5.0g, 나한과추출물 0.005g, 복합황금추출물 0.05g, 구연산 0.04g, 비타민 C 0.007g, 자몽종자추출물 0.08g, 폴리덱스트로즈(중합체 90%) 1.7g을 정제수로 100중량이 되게 혼합하여 발효홍삼음료를 제조하였다.Fermented red ginseng concentrate (Brix32), 2 ~ 3g as a main ingredient, mixed fermented red ginseng concentrate (Brix34) 6 ~ 7g, mixed with medicinal herbs, 2 ~ 4.4g of bark tree extract (Brix50), 2.8 ~ 4.0g, as extract of red ginseng beverage (Brix50) Cordyceps sinensis extract (Brix50) 3.0 ~ 4.5g, Ssanghwa extract (Brix50) 2.7 ~ 5.0g, ganoderma lucidum extract (Brix50) 2.4 ~ 3.9g, licorice extract (Brix50) 3.4 ~ 5.0g, unsweetened fruit extract 0.005g, complex golden extract 0.05 g, citric acid 0.04g, vitamin C 0.007g, grapefruit seed extract 0.08g, polydextrose (90% polymer) 1.7g mixed to 100% by purified water to prepare a fermented red ginseng beverage.
배합에 사용되는 부원료들은 다음과 같이 제조하였다.Subsidiary materials used in the formulation were prepared as follows.
동충하초 추출액은, 정제수 3000g에 대하여 상기 녹차잎 100g을 혼합하여 동충하초 혼합물을 생성하고, 동충하초 혼합물을 80℃의 온도에서 6시간 동안 가열하고, 가열된 동충하초 혼합물을 여과 및 농축(Brix 50)하여 생성하였다. Cordyceps sinensis extract was produced by mixing 100 g of the green tea leaves with respect to 3000 g of purified water to produce a cordyceps fungus mixture, heating the cordyceps fungus mixture at a temperature of 80 ° C. for 6 hours, and filtering and concentrating the heated cordyceps fungus mixture (Brix 50). .
헛개나무 추출액은 정제수 5000g에 대하여 헛개나무 100g, 내열성 아밀라제 0.5g을 혼합하여 헛개나무 혼합물을 생성하고, 헛개나무 혼합물을 120℃의 온도에서 6시간 동안 가열하고, 여과 및 농축(Brix 50)하여 생성하였다.The bark extract is mixed with 100 g of bark tree and 0.5 g of heat-resistant amylase to 5000 g of purified water to form a bark tree mixture, and the bark tree mixture is heated at a temperature of 120 ° C. for 6 hours, filtered and concentrated (Brix 50). It was.
천궁 추출액은, 정제수 8000g에 대하여 천궁 100g, 셀룰라제 0.3g, 글루코아밀라제 0.3g을 혼합하여 천궁 혼합물을 생성하고, 50℃의 온도로 3시간 동안 가열하였다. 가열된 천궁 혼합물을 여과 및 농축(Brix50)하여 생성하였다.The archery extract was mixed with 100 g of archery, 0.3 g of cellulase, and 0.3 g of glucoamylase with respect to 8000 g of purified water to form a arch mixture, and heated to a temperature of 50 ° C. for 3 hours. The heated arch mixture was produced by filtration and concentration (Brix50).
감초 추출액은, 정제수 5000g에 대하여 쌍화 100g, 셀룰라제 0.3g, 비스코자임(viscozyme) 0.3g을 혼합하여 감초 혼합물을 생성하고 55℃의 온도로 3시간 동안 가열하고, 가열된 감초 혼합물을 여과 및 농축(Brix50)하여 생성하였다.The licorice extract is mixed with 100 g of purified water, 0.3 g of cellulase, and 0.3 g of viscozyme with respect to 5000 g of purified water to form a licorice mixture, heated to a temperature of 55 ° C. for 3 hours, and the heated licorice mixture is filtered and concentrated. Produced by (Brix50).
영지버섯 추출액은, 정제수 1200g에 대하여 영지버섯 100g, 내열성 아밀라제 0.5g을 혼합하여 영지버섯 혼합물을 생성하고, 120℃의 온도로 6시간 동안 1차 가열하고, 당화효소 0.3g, 셀룰라제 0.3g을 더 혼합하여 60℃의 온도에서 6시간 동안 2차 가열하고, 2차 가열된 영지버섯 혼합물을 여과 및 농축(Brix50)하여 생성하였다.The ganoderma lucidum extract was prepared by mixing 100 g of ganoderma lucidum mushroom and 0.5 g of heat-resistant amylase with respect to 1200 g of purified water to produce a ganoderma lucidum mixture, which was first heated to a temperature of 120 ° C. for 6 hours, and 0.3 g of glycosylase and 0.3 g of cellulase The mixture was further heated for 2 hours at a temperature of 60 ° C., and the secondary heated Ganoderma lucidum mixture was produced by filtration and concentration (Brix50).
쌍화 추출액은, 정제수 1200g에 대하여 쌍화 100g, 내열성 아밀라제 0.5g을 혼합하여 영지버섯 혼합물을 생성하고, 120℃의 온도로 6시간 동안 1차 가열하고, 당화효소 0.3g, 셀룰라제 0.3g을 더 혼합하여 60℃의 온도에서 6시간 동안 2차 가열하고, 2차 가열된 쌍화 혼합물을 여과 및 농축(Brix50)하여 생성하였다.The Ssanghwa extract is mixed with 100 g of purified water and 0.5 g of heat-resistant amylase to 1200 g of purified water to form a ganoderma lucidum mixture, which is first heated at a temperature of 120 ° C. for 6 hours, and 0.3 g of saccharase and 0.3 g of cellulase are further mixed. Second heating at a temperature of 60 ° C. for 6 hours, and the secondary heated paired mixture was produced by filtration and concentration (Brix50).
실시예 4) 배합 음료의 여과, 살균 및 충진포장Example 4 Filtration, Sterilization and Filling of Blended Beverages
배합 조성물을 여과한 후 음료 혼합물을 98℃의 온도에서 2~5분간 살균한다. 그리고 살균이 완료되면 음료 혼합물에 복합허브향 0.2g을 첨가한다. 살균단계에서 살균되고 허브향이 첨가된 음료 혼합물을 용기에 충진하여 냉각한 후 캡으로 밀봉 한다.After filtering the formulation composition, the beverage mixture is sterilized for 2-5 minutes at a temperature of 98 ℃. When sterilization is complete, add 0.2 g of mixed herb flavor to the beverage mixture. In the sterilization stage, the beverage mixture sterilized and added to the herb flavor is filled into a container, cooled, and sealed with a cap.
실험예 1. α-글루코시다제 및 α-아밀라제 저해활성 측정Experimental Example 1. Measurement of α-glucosidase and α-amylase inhibitory activity
발효홍삼과 약용식물 첨가 발효홍삼 추출액의 항당뇨효능 검증을 위하여 당의 소화 및 흡수에 관여하는 α-글루코시다제와 α-아밀라제에 대한 저해활성 정도를 테스트하였다.In order to verify the antidiabetic effect of fermented red ginseng extract and fermented red ginseng extract, the inhibitory activity of α-glucosidase and α-amylase involved in sugar digestion and absorption was tested.
α-글루코시다제는 소장점막에 존재하는 효소로서 다당류의 탄수화물을 단당류로 분해하는 효소로서, 소장점막내에서 α-글루코시다제의 활성을 저해함으로써 glucose의 흡수를 지연시켜 식후혈당의 급격한 상승을 억제할 것으로 기대하였다.α-glucosidase is an enzyme present in the small intestine mucosa. It is an enzyme that breaks down the carbohydrates of polysaccharides into monosaccharides. It inhibits the activity of α-glucosidase in the small intestine mucosa, delaying glucose absorption and causing a rapid rise in postprandial blood glucose. It was expected to be suppressed.
α-글루코시다제 저해활성은 니트로페놀 분석법을 응용하여 측정하였다. 0.2U/mL α-글루코시다제 효소액 50uL, 12mM p-니트로페놀-α-D-글루코피라노사이드 100uL, 샘플 50uL 및 0.1M 인산칼륨 완충액 (pH 6.8) 50uL와 혼합하여 37℃에서 20분간 전배양한 후 0.1M NaOH 100uL를 가하여 반응을 정지시키고 405nm에서 흡광도를 측정하였다. 효소활성의 저해정도는 다음 식에 의하여 산출하였다.α-glucosidase inhibitory activity was measured by applying nitrophenol assay. 50 μL of 0.2 U / mL α-glucosidase enzyme solution, 100 μL of 12 mM p -nitrophenol-α-D-glucopyranoside, 50 μL of sample and 50 μL of 0.1 M potassium phosphate buffer (pH 6.8) were mixed at 37 ° C. for 20 minutes. After incubation, 100 M of 0.1 M NaOH was added to stop the reaction, and the absorbance was measured at 405 nm. The degree of inhibition of enzyme activity was calculated by the following equation.
α-글루코시다제 저해활성(%) = [1-(시료처리구의 흡광도/대조구의 흡광도)]×100α-glucosidase inhibitory activity (%) = [1- (absorbance of sample / absorbance of control)] × 100
α-아밀라제 저해는 소장에서 전분의 소화를 저해하여 포도당의 흡수를 지연시킴으로써 혈당 조절목적으로 이용된다. α-amylase inhibition is used for glycemic control by inhibiting the digestion of starch in the small intestine and delaying the absorption of glucose.
α-아밀라제 저해활성은 환원당 분석법을 응용하여 효소원으로 사람의 타액 아밀라제를 사용하고 기질로서 0.5% 전분을 이용하여 효소활성을 측정하였다. 즉, 효소액 50uL, 시료 50uL, 0.5% 전분 100uL, 인산칼륨 완충액(pH 6.8) 50uL와 혼합하여 37℃에서 20분간 전배양한 후 48mM DNS 발색시약(3,5-dinitrosalicylic acid and 30% sodium potassium tartarate in 0.5M NaOH) 250uL를 넣고 100℃에서 10분간 끓여 발색시킨 후 충분히 냉각시켰다. 이 반응액에 3배량의 물을 가하고 잘 교반 한 후 540nm에서 흡광도를 측정하였다. 효소활성의 저해정도는 다음 식에 의하여 산출하였다.α-amylase inhibitory activity was measured by using human salivary amylase as an enzyme source using a reducing sugar assay and 0.5% starch as a substrate. In other words, 50uL of enzyme solution, 50uL of sample, 100uL of 0.5% starch, 50uL of potassium phosphate buffer (pH 6.8), pre-incubated at 37 ° C for 20 minutes, and then 48mM DNS coloring reagent (3,5-dinitrosalicylic acid and 30% sodium potassium tartarate) in 0.5M NaOH) 250uL and boiled at 100 ℃ for 10 minutes to develop a color and then cooled sufficiently. Three times the amount of water was added to the reaction solution, the mixture was stirred well, and the absorbance was measured at 540 nm. The degree of inhibition of enzyme activity was calculated by the following equation.
α-아밀라제 저해활성(%) = [1-(시료처리구의 흡광도/대조구의 흡광도)]×100α-amylase inhibitory activity (%) = [1- (absorbance of sample / absorbance of control)] × 100
발효홍삼과 한약재 첨가 발효홍삼의 α-글루코시다제와 α-아밀라제 효소에 대한 저해활성도는 표 1에서 보는 바와 같다.Inhibitory activity of fermented red ginseng and Chinese herbal medicines on α-glucosidase and α-amylase enzymes is shown in Table 1.
한약재 첨가 발효홍삼의 α-글루코시다제에 대한 저해활성은 제2형 당뇨치료제인 아카보스(acarbose)보다 높았고, α-글루코시다제에 대한 저해활성은 아카보스와 유의적으로 비슷한 수준을 나타내어 본 발명의 발효홍삼이 식후혈당 개선제로서의 효능을 확인하였다.The inhibitory activity of α-glucosidase of fermented red ginseng supplemented with medicinal herbs was higher than acarbose, a type 2 diabetes treatment, and the inhibitory activity against α-glucosidase was significantly similar to that of acarbose. Fermented red ginseng was confirmed as a post-prandial blood sugar improving agent.
실험예 2. 발효홍삼 및 한약재첨가 발효홍삼의 당뇨유발 쥐(Rat)에서의 혈당변화Experimental Example 2 Changes in Blood Glucose Levels of Fermented Red Ginseng and Herbal Supplements
발효 홍삼(FRG) 및 약용식물 첨가 발효홍삼(FRGM)의 혈당수준 개선효과를 확인하기 위하여 상기의 제조방법에 따라 발효, 농축하여 각각 동결건조하여 분말화한 다음, -20℃에 보관하면서 동물식이 실험에 사용하였다. In order to confirm the effect of fermented red ginseng (FRG) and medicinal plants on improving blood glucose level, fermented and concentrated according to the above production method, concentrated and freeze-dried, and then powdered and stored at -20 ℃. It was used for the experiment.
실험동물은 체중 180±10g의 SD(Sprague-Dawley)계 수컷 Rat(오리엔트바이오)를 구입하여 실험하였다. 사육실의 환경은 온도 23± 2℃, 습도 60± 5%, 명암주기 12시간으로 일정하게 유지하였고, 1주일간 rat용 고형사료와 물을 충분히 공급하여 환경에 적응시킨 후 3주간 실험을 실시하였다.Experimental animals were tested by purchasing Sprague-Dawley male rats (orient bio) weighing 180 ± 10 g. The environment of the breeding room was kept constant at a temperature of 23 ± 2 ℃, a humidity of 60 ± 5%, and a contrast cycle of 12 hours, and the experiment was conducted for 3 weeks after being fully supplied with rat solid feed and water for 1 week.
1주일간 적응시킨 rat에 정상군의 경우 생리식염수를 복강투여 하였고, 정상군을 제외한 다른 군에서는 스트렙토조신(STZ, 60mg/kg bw)을 1회 복강투여하였다. 48시간 후 혈당을 측정하여 당뇨 유발을 확인한 후 실험에 사용하였다. 그리고 시료투여군의 경우 3주간 각 시료를 매일 일정한 시간에 경구 투여하였다. 이들 시료는 각각 증류수에 녹여 200mg/kg의 농도로 투여하였으며, 고형사료와 물은 충분히 공급하면서 사육하였다. Rats who were acclimated for 1 week were intraperitoneally administered saline in normal group, and streptozosin (STZ, 60mg / kg bw) was intraperitoneally administered in other groups except normal group. After 48 hours, blood glucose was measured and confirmed in diabetes. In the case of the sample administration group, each sample was orally administered at a predetermined time every day for three weeks. These samples were each dissolved in distilled water and administered at a concentration of 200 mg / kg, and were fed with sufficient supply of solid feed and water.
식이 섭취량은 3일에 한번 식이 잔량을 측정하여 식이 제공량으로부터 뺀 값을 기록하였으며, 체중은 매주 일정한 시간에 측정하였다. 또한 사육기간 동안의 혈당 변화를 관찰하기 위해 매주 1회 12시간 이상 절식시킨 후 꼬리정맥의 혈액을 채취하여 혈당측정기(ACCU-CHEK Sensor, Germany)로 측정하였다. The dietary intake was measured by subtracting the dietary amount by measuring the remaining amount of diet once every three days, and the weight was measured at a certain time every week. In addition, in order to observe the change in blood glucose during the breeding period, after fasting for more than 12 hours once a week, blood from the tail vein was collected and measured with a blood glucose meter (ACCU-CHEK Sensor, Germany).
당뇨유발쥐에 발효홍삼과 약용식물 첨가 발효홍삼을 각각 3주 동안 식이하면서 혈당의 변화를 측정한 결과는 표 2에서 보는 바와 같이 발효홍삼과 한약재 첨가 발효홍삼을 투여한 쥐는 1주째부터 혈당이 떨어지기 시작하여 3주차에는 당뇨유발쥐에 비해 현저히 혈당이 감소되는 것을 확인하였고, 한약재 첨가 발효홍삼이 발효홍삼보다 혈당감소 효과가 더 우수함을 확인하였다.As a result of measuring fermentation red ginseng and medicinal plant added fermented red ginseng for 3 weeks, the results of blood glucose change were as shown in Table 2. It was confirmed that blood glucose was significantly reduced at 3 weeks after diabetic rats, and the effect of reducing red blood sugar was higher than that of fermented red ginseng.
당뇨유발쥐
Diabetic Rats
발효홍삼
Fermented Red Ginseng
한약재 첨가 발효홍삼
Fermented Red Ginseng with Herbal Medicine
실험예 3. 발효홍삼 음료 배합조성 및 관능평가Experimental Example 3. Composition and Sensory Evaluation of Fermented Red Ginseng Beverage
각각의 소재를 활용하여 관능평가에 사용된 배합비는 아래의 표 3과 같다.The mixing ratios used for the sensory evaluation using the respective materials are shown in Table 3 below.
또한 관능평가의 결과는 표 4에 나타내었다. In addition, the results of the sensory evaluation are shown in Table 4.
(Brix32)Fermented Red Ginseng Extract with Herbal Medicine
(Brix32)
(Brix34)Fermented Red Ginseng Extract
(Brix34)
(Brix50)Barn Tree Concentrate
(Brix50)
(Brix50)Cheongung Concentrate
(Brix50)
(Brix50)Cordyceps Sinensis Concentrate
(Brix50)
(Brix50)Ssanghwa Concentrate
(Brix50)
(Brix50)Ganoderma lucidum concentrate
(Brix50)
(Brix50)Licorice Concentrate
(Brix50)
(중합체90%이상)Polydextrose
(90% or more of the polymer)
위의 음료조성 배합별 관능평가는 색상, 성상, 맛, 풍미, 종합적기호도의 다섯 개 항목으로 실시하였으며, 가장 좋음이 5점, 좋음이 4점, 보통 3점, 나쁨이 2점, 아주 나쁨을 1점으로 하여 산출하였다. The sensory evaluation of each beverage composition was conducted in five categories: color, appearance, taste, flavor, and overall symbol. The best 5 points, good 4 points, normal 3 points, bad 2 points, and very bad It calculated as one point.
No. 127번 배합 조성의 음료가 관능평가결과 종합적 기호도가 가장 높게 나타났다. No. In the sensory evaluation, the beverage with the 127th composition showed the highest overall acceptability.
도 1은 본 발명의 일 실시예에 따른 발효홍삼 농축액 및 한약재 첨가 발효홍삼 농축액의 제조방법을 도식화한 공정도이다. 1 is a process diagram illustrating a method for preparing a fermented red ginseng concentrate and a medicinal herb added fermented red ginseng concentrate according to an embodiment of the present invention.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090044419A KR101113931B1 (en) | 2009-05-21 | 2009-05-21 | A method for preparation of fermented red ginseng drink mixed with medical plants extracts and a drink composition comprising the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090044419A KR101113931B1 (en) | 2009-05-21 | 2009-05-21 | A method for preparation of fermented red ginseng drink mixed with medical plants extracts and a drink composition comprising the same |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20100125618A true KR20100125618A (en) | 2010-12-01 |
KR101113931B1 KR101113931B1 (en) | 2012-03-14 |
Family
ID=43503693
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020090044419A KR101113931B1 (en) | 2009-05-21 | 2009-05-21 | A method for preparation of fermented red ginseng drink mixed with medical plants extracts and a drink composition comprising the same |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101113931B1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101247589B1 (en) * | 2010-12-03 | 2013-03-26 | 이재호 | Fermented tea using wood-cultivated ginseng, and manufacturing method thereof |
CN103622017A (en) * | 2013-11-28 | 2014-03-12 | 潘新华 | Ganoderma lucidum and cordyceps militaris granules |
CN103932342A (en) * | 2014-04-28 | 2014-07-23 | 黑龙江华药生物科技有限公司 | Cordyceps militaris biowater and preparation method thereof |
CN106389483A (en) * | 2016-10-21 | 2017-02-15 | 彭友良 | Medical fungi formula for preventing and treating diabetes and preparation method of medical fungi formula |
KR101958439B1 (en) * | 2018-11-19 | 2019-03-15 | 태웅식품 주식회사 | Method for producing Hovenia dulcis beverage product comprising Hovenia dulcis mixed concentrate |
CN110521817A (en) * | 2018-05-23 | 2019-12-03 | 周红云 | A kind of blue or green money willow blood sugar reducing health teabag drink and preparation method thereof |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104814192A (en) * | 2015-05-14 | 2015-08-05 | 安徽富从春商贸有限公司 | White mulberry root bark-containing healthcare tea beverage |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100618171B1 (en) * | 2003-04-30 | 2006-08-29 | 김재백 | Fermented red ginseng containing ginseng saponin degradate and its manufacturing method |
-
2009
- 2009-05-21 KR KR1020090044419A patent/KR101113931B1/en not_active IP Right Cessation
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101247589B1 (en) * | 2010-12-03 | 2013-03-26 | 이재호 | Fermented tea using wood-cultivated ginseng, and manufacturing method thereof |
CN103622017A (en) * | 2013-11-28 | 2014-03-12 | 潘新华 | Ganoderma lucidum and cordyceps militaris granules |
CN103932342A (en) * | 2014-04-28 | 2014-07-23 | 黑龙江华药生物科技有限公司 | Cordyceps militaris biowater and preparation method thereof |
CN106389483A (en) * | 2016-10-21 | 2017-02-15 | 彭友良 | Medical fungi formula for preventing and treating diabetes and preparation method of medical fungi formula |
CN110521817A (en) * | 2018-05-23 | 2019-12-03 | 周红云 | A kind of blue or green money willow blood sugar reducing health teabag drink and preparation method thereof |
KR101958439B1 (en) * | 2018-11-19 | 2019-03-15 | 태웅식품 주식회사 | Method for producing Hovenia dulcis beverage product comprising Hovenia dulcis mixed concentrate |
Also Published As
Publication number | Publication date |
---|---|
KR101113931B1 (en) | 2012-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101113931B1 (en) | A method for preparation of fermented red ginseng drink mixed with medical plants extracts and a drink composition comprising the same | |
KR101339706B1 (en) | A compound for immune strengthen inclusion reducing the bitterness of red ginseng, the extract of immune, and the probiotics | |
CN103156896A (en) | Preparation method for novel red ginseng using reduced-pressure drying after high temperature high pressure process | |
KR20180061062A (en) | Composition for preventing or improving diabetes mellitus comprising momrdica charantia (l.) extract, chrysanthemum zawadskii var. latilobum and paeonia lactiflora extract as an effective ingredient | |
KR20030026939A (en) | The effective tea compositions with guava leaf as chief element for remedy against diabetes, obesity and aging, and functional foods | |
CN109069562A (en) | Polysaccharide digests inhibitor | |
KR102243873B1 (en) | Fermented pills for reducing and preventing premature dementia and manufacturing methods thereof | |
KR101774769B1 (en) | Composition for medicinal herbal tea and manufacturing method of composition for medicinal herbal by supercritical fluid extraction and manufacturing method of carbonated beverage and health beverage thereof | |
KR20110075593A (en) | Antibiotic functional food containing extract of platycodon grandiflorum and garlic for preventing and improving respiratory organ disease | |
KR101270599B1 (en) | Fermented red ginseng composition containing fermented red ginseng and medical plant extracts exhibiting antidiabetic activity | |
CN106581166A (en) | Anti-fatigue food, health product or pharmaceutical composition | |
KR100848686B1 (en) | A FERMENTED GINSENG COMPOSITION STRENGTHENED SIMULTANEOUSLY WITH γ-AMINOBUTYRIC ACID AND BIOCONVERSION SAPONIN BY LACTIC ACID BACTERIA | |
CN105831318A (en) | Polypeptide tea for blood glucose reduction and manufacturing method of polypeptide tea | |
CN108260682A (en) | A kind of hypoglycemic, reducing blood lipid and the health protection tea of blood pressure lowering | |
KR102282839B1 (en) | Composition for relieving or improving hangover | |
CN106421491A (en) | Formula of radix helicteris oral liquid with blood glucose reducing effect and preparation method | |
KR101808808B1 (en) | Compositions for preventing and treating diabetes or diabetic complications comprising extracts of Acer tegmentosum Maximowoca and Magnolia officinalis Rehd. et Wils. | |
KR101668447B1 (en) | Composition for curing hanover and health functional foods composition comprising the same | |
US20080311229A1 (en) | Functional Food Composition For Treating Allergy, Natural Tea Using the Same and the Manufacturing Method Thereof | |
KR20100008220A (en) | Composition for preventing and treating colon cancer containing extract of mushroom and herb medicine | |
KR101003463B1 (en) | A process forpreparing fermented soybean pills efficacious against atopic dermatitis | |
KR100642801B1 (en) | Anti-diabetic food composition comprising extracts from natural herbal materials and pear and process for preparing the same | |
KR100551464B1 (en) | Composition comprising an extract of Saururus chinensis BAILL. for preventing and treating diabetes mellitus | |
KR102203094B1 (en) | Composition for preventing and improving menstrual pain and skin troubles | |
KR102003354B1 (en) | Composition comprising Spike mulberry mistletoe extract for treating diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20150121 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20160127 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20170317 Year of fee payment: 6 |
|
LAPS | Lapse due to unpaid annual fee |